GSK-1070916 (GMP)

GSK-1070916 (GMP) is GSK-1070916 produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A[1][2].

942918-07-2

GSK-1070916A (GMP)

12352005

Apoptosis; Aurora Kinase

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Cancer

O=C(NC1=CC=C(C2=NN(C=C2C3=C4C(NC(C5=CC=CC(CN(C)C)=C5)=C4)=NC=C3)CC)C=C1)N(C)C

C30H33N7O

507.63

[1]Adams ND, et al. Discovery of GSK-1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53 (10) :3973-4001.|[2]Hardwicke MA, et al. GSK-1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009 Jul;8 (7) :1808-17.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-70044G/

GMP Small Molecules

No Development Reported